Navigation Links
Ampio Pharmaceuticals Schedules 2012 Update Webcast
Date:5/14/2012

GREENWOOD VILLAGE, Colo., May 14, 2012 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NASDAQ: AMPE), a biopharmaceutical company conducting clinical trials on its three lead drugs (Ampion™, Optina™ and Zertane™), licensing distribution of those drugs and engaged in further drug development), will hold a webcast on Wednesday, May 16, 2012, at 4:15 p.m. EDT.  Management will outline the Company's 2012 progress, provide a detailed review for each of its three lead products and update the status of licensing and collaboration efforts.

Dial-in Information

United States:  800.295.3991
International:  617.614.3924

Passcode: 54743349

The call also can be accessed at www.ampiopharma.com

Replay Information

United States:  888 286.8010
International:  617 801.6888

Passcode: 29004533

The replay will be posted approximately two hours after the completion of the live event, and it will be available for 7 days.  Ampio will post a replay of the May 16, 2012 call on its website. 

About Ampio Pharmaceuticals

Ampio Pharmaceuticals, Inc. develops innovative proprietary drugs for metabolic disease, eye disease, kidney disease, inflammation, CNS disease, and male sexual dysfunction. The product pipeline includes new uses for previously approved drugs and new molecular entities ("NMEs"). By concentrating on development of new uses for previously approved drugs, approval timelines, costs and risk of clinical failure are reduced because these drugs have strong potential to be safe and effective while their shorter development times can significantly increase near term value. A key strategy includes actively exploring partnership, licensing and other collaboration opportunities to maximize Ampio's product development programs. For more information about Ampio, please visit our website, www.ampiopharma.com.

Contact
Investor Relations, 
Ampio Pharmaceuticals, Inc.
 720-437-6500


'/>"/>
SOURCE Ampio Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Four Californians Selected As Breakaway from Cancer® Champions To Be Honored During Amgen Tour of California
2. Ampio Awarded US and Canadian Patents that will Bolster the Commercialization of Optina™ for the treatment of Diabetic Macular Edema (DME)
3. Ampio Strengthens Patent Protection for Lead Drug Ampion™
4. Ampio Announces Positive Preliminary Update on the Optina™ Clinical Trial to Treat Diabetic Macular Edema and Decision to Conclude the Study Ahead of Schedule
5. Champions Oncology Reports Fiscal 2012 Third Quarter Financial Results
6. Ampio Pharmaceuticals Reports Full-Year 2011 Financial Results and Milestone Highlights for 2011
7. Ampio Pharmaceuticals Schedules 2012 Outlook Webcast
8. Executive Changes at Ampio
9. Ampio Pharmaceuticals Schedules Webcast to Update Shareholders
10. Ampio Pharmaceuticals Announces Registered Direct Common Stock Offering of Approximately $9.436 Million
11. Ampio Responds to Recent Publications by Anonymous Short Sellers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... and SAN CLEMENTE, Calif. , June 24, 2016 ... mobile pulmonary function testing company, is now able to perform sophisticated ... by ndd Medical Technologies , Inc. Patients ... hospital-based labs.  Thanks to ndd,s EasyOne PRO ® , ARL patients ... get any needed testing done in the comfort of her own ...
(Date:6/24/2016)... , June 24, 2016 VolitionRx ... of Dr. Edward Futcher to the ... effective June 23, 2016.Dr. Futcher was also appointed ... Governance Committees.  As a non-executive member of the ... and strategic counsel to VolitionRx in connection with ...
(Date:6/23/2016)... BEVERLY HILLS, Calif. , June 23, 2016 ... faced the many challenges of the current process. Many of ... option because of the technical difficulties and high laboratory costs ... would have to offer it at such a high cost ... to afford it. Dr. Parsa Zadeh , ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson has dedicated ... has implemented orthobiologic procedures as a method for treating his patients. The procedure ... doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use to ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Those who ... with these feelings, many turn to unhealthy avenues, such as drug or alcohol abuse, ... Marne, Michigan, has released tools for healthy coping following a traumatic event. , Trauma ...
(Date:6/24/2016)... ... 2016 , ... Global law firm Greenberg Traurig, P.A. announced that 20 Florida ... their peers for this recognition are considered among the top 2 percent of lawyers ... as members of this year’s Legal Elite Hall of Fame: Miami Shareholders Mark ...
(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. are ... Code Talker Award, an essay contest in which patients and their families pay tribute ... presented at the 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) ...
(Date:6/24/2016)... ... 24, 2016 , ... Strategic Capital Partners, LLC (SCP) in ... investment capital for emerging technology companies. SCP has delivered investment events and ... more than a million dollars of capital investment for five companies. ...
Breaking Medicine News(10 mins):